In multivariate analysis , the growth rate was @ mm/year in eyes receiving bevacizumab and @ mm/year in eyes receiving ranibizumab ( difference , @ mm/yr ; @ % confidence interval -LSB- CI -RSB- , @-@ @ ; P = @ ) .